

AVITA MEDICAL JUNE 2009 APPENDIX 4E

Summary of Year ending 30 June 2009:

- Sales were up approximately 266% from the same period of the previous year, with sales for the year of \$2,882,741 versus \$1,085,087. The Company holds an additional \$657,272 in trade and other receivables;
- Losses due to Continuing Operations before tax decreased by \$7,417,690 or 59% (\$5,128,292 versus \$12,545,982);
- Awarded US\$1.5 million grant from the US Armed Forces to accelerate ReCell approval in the US with initial payment of AU\$475,000 received in August 2009 (not recognised in 30 June 2009 year end cash or receivables);
- Secured \$5 million funding facility through Fortrend Securities (refer to announcement on 20 & 22 July 2009);
- Completed major revision of products manufacturing process including the relocation of our spacer manufacturing to a new GMP facility in Malaysia and reduction of production costs by more than 30%;
- Receipt of ISO 9001:2000 Quality Management System Certification and ISO 13485:2003 Medical Devices Certification allowing Avita Medical to CE mark its regenerative and respiratory products for sales in European markets;
- Implementation of major changes in organisational structure and focus including appointment of new CEO and senior management in July 2008.

For personal use only

Appendix 4E

Full year Report

30 June 2009

AVITA MEDICAL LIMITED

ABN 28 058 466 523

Results for announcement to the market

			June 2009
Financial Results			\$
Revenue from ordinary activities (1)	Up	67%	3,267,427
Loss from ordinary activities after tax attributable to members (2)	Down	58%	5,128,292
Net loss for the period attributable to members (2)	Down	58%	5,128,292
Dividends	Amount per Ordinary Security	Franked amount per security	
2009 interim dividend	Nil	Nil	
2008 interim dividend	Nil	Nil	
Record date for determining entitlements to interim dividends	N/A		
Net Tangible Asset Backing	June 2009	June 2008	
Net tangible asset backing per ordinary security	\$0.051	\$0.098	

Other explanatory notes

- (1) Total revenue is 67% higher than the prior period reflecting the impact of the Visiomed acquisition in February 2008.
- (2) The loss for the year is down 58% from the prior year. Operating expenses excluding amortisation and impairment of intangible assets have increased by \$980,388 representing an increase of 17%. The prior year loss also included amortisation and impairment of intangible assets of \$8,157,297.

AVITA MEDICAL LIMITED
 PRELIMINARY FINAL REPORT
 INCOME STATEMENT
 FOR THE YEAR ENDED 30 JUNE 2009

	Notes	Consolidated	
		2009	2008
		\$	\$
Continuing operations			
Sale of goods		2,882,741	1,085,087
Finance revenue		384,686	869,919
Revenue	2	<u>3,267,427</u>	<u>1,955,006</u>
Cost of sales		(1,021,288)	(514,572)
Gross profit		<u>2,246,139</u>	<u>1,440,434</u>
Other income	2	51,713	7,637
Operating costs			
Administrative expenses		(4,791,105)	(4,156,429)
Research and development expenses		(225,323)	(171,236)
Sales and marketing expenses		(1,703,449)	(1,453,485)
Finance costs	2	(97,267)	(55,606)
Amortisation of goodwill		(609,000)	(232,000)
Impairment of intellectual property		-	(7,925,297)
Loss from continuing operations before tax		<u>(5,128,292)</u>	<u>(12,545,982)</u>
Income tax benefit/(expense)		-	357,702
Net loss attributable to members of Avita Medical Limited		<u>(5,128,292)</u>	<u>(12,188,280)</u>
Basic loss per share attributable to ordinary equity holders of the parent	3	\$0.0549	\$0.2040
Diluted loss per share attributable to ordinary equity holders of the parent	3	\$0.0549	\$0.2040

For personal use only

AVITA MEDICAL LIMITED
 PRELIMINARY FINAL REPORT
 BALANCE SHEET AS AT 30 JUNE 2009

	Notes	Consolidated	
		2009	2008
		\$	\$
ASSETS			
Current Assets			
Cash and cash equivalents	4	3,477,104	8,464,669
Other financial assets	5	400,000	400,000
Trade and other receivables	6	657,272	1,130,525
Prepayments		254,316	263,348
Inventories	7	883,327	747,519
Total Current Assets		5,672,019	11,006,061
Non-Current Assets			
Other financial assets	8	200,000	400,000
Plant & equipment	9	154,557	388,164
Intangible assets	10	3,802,888	4,411,888
Total Non-Current Assets		4,157,445	5,200,052
TOTAL ASSETS		9,829,464	16,206,113
LIABILITIES			
Current Liabilities			
Trade and other payables	11	1,095,037	2,139,823
Interest bearing liabilities	12	-	33,334
Provisions	13	76,554	52,721
Total Current Liabilities		1,171,591	2,225,878
Non-Current Liabilities			
Other term liabilities	14	67,992	436,380
Total Non-Current Liabilities		67,992	436,380
TOTAL LIABILITIES		1,239,583	2,662,258
NET ASSETS		8,589,881	13,543,855
EQUITY			
Equity attributable to equity holders of the parent			
Contributed equity	15	86,824,320	86,824,320
Accumulated losses	16	(81,400,222)	(76,271,930)
Reserves	16	3,165,783	2,991,465
TOTAL EQUITY		8,589,881	13,543,855

AVITA MEDICAL LIMITED
PRELIMINARY FINAL REPORT
CASH FLOW STATEMENT
FOR THE YEAR ENDED 30 JUNE 2009

	Consolidated	
	2009	2008
	\$	\$
Cash flows from operating activities		
Receipts from customers	2,423,558	987,659
Payments to suppliers and employees	(8,127,905)	(6,132,718)
Government grants received	46,058	6,144
Tax refund received	126,862	604,056
Interest received	334,686	698,418
Interest paid	(74,099)	(27,834)
Royalties and other income received	558,249	172,994
	<u>(4,712,591)</u>	<u>(3,691,281)</u>
Net cash flows used in operating activities		
Cash flows from investing activities		
Net cash acquired on acquisition	-	845,509
Purchase of plant & equipment	(83,717)	(112,411)
Purchase of intellectual property	(344,081)	(90,278)
Proceeds from sale of plant & equipment	5,455	15,123
	<u>(422,343)</u>	<u>657,943</u>
Net cash flows provided by (used in) investing activities		
Cash flows from financing activities		
Proceeds from issue of shares and options	-	2,957
Repayment of borrowings	(52,631)	(13,492)
	<u>(52,631)</u>	<u>(10,535)</u>
Net cash flows from financing activities		
Net increase/(decrease) in cash and cash equivalents	(5,187,565)	(3,043,873)
Cash and cash equivalents at beginning of period	9,264,669	12,308,542
Cash and cash equivalents at end of period	4,077,104	9,264,669

AVITA MEDICAL LIMITED
 PRELIMINARY FINAL REPORT
 STATEMENT OF CHANGES IN EQUITY
 FOR THE YEAR ENDED 30 JUNE 2009

Consolidated	Contributed Equity \$	Accumulated Losses \$	Other Reserves \$	Total \$
At 1 July 2008	86,824,320	(76,271,930)	2,991,465	13,543,855
Currency translation differences	-	-	46,997	46,997
Total income and expense for the period recognised directly in equity	-	-	46,997	46,997
Loss for the period	-	(5,128,292)	-	(5,128,292)
Total income and expense for the period	-	(5,128,292)	46,997	(5,081,295)
Cost of share-based payment	-	-	127,321	127,321
At 30 June 2009	86,824,320	(81,400,222)	3,165,783	8,589,881

Consolidated	Contributed Equity \$	Accumulated Losses \$	Other Reserves \$	Total \$
At 1 July 2007	74,095,318	(64,083,650)	2,929,097	12,940,765
Currency translation differences	-	-	(28,696)	(28,696)
Total income and expense for the period recognised directly in equity	-	-	(28,696)	(28,696)
Loss for the period	-	(12,188,280)	-	(12,188,280)
Total income and expense for the period	-	(12,188,280)	(28,696)	(12,216,976)
Issue of share capital	12,729,002	-	-	12,729,002
Cost of share-based payment	-	-	91,064	91,064
At 30 June 2008	86,824,320	(76,271,930)	2,991,465	13,543,855

For personal use only

AVITA MEDICAL LIMITED
 NOTES TO THE PRELIMINARY FINAL REPORT
 FOR THE YEAR ENDED 30 JUNE 2009

1. BASIS OF PREPARATION

The financial report has been prepared in accordance with the recognition and measurement requirements but not the disclosure requirements of Australian Accounting Standards.

The financial report has been prepared on a going concern basis, which contemplates the continuity of normal business activity, and the realisation of assets and settlement of liabilities in the ordinary course of business.

The financial report is presented in Australian dollars.

2. REVENUES AND EXPENSES

Revenue and Expenses from Continuing Operations

	Consolidated	
	2009	2008
	\$	\$
(a) Revenue		
Sale of goods	2,882,741	1,085,087
Other revenue	384,686	869,919
	<u>3,267,427</u>	<u>1,955,006</u>
<i>Breakdown of other revenue:</i>		
Bank interest receivable	334,686	698,418
Other	50,000	171,501
	<u>384,686</u>	<u>869,919</u>
	Consolidated	
	2009	2008
	\$	\$
(b) Other income		
Government grants	46,058	6,144
Other revenue	5,655	1,493
	<u>51,713</u>	<u>7,637</u>
	Consolidated	
	2009	2008
	\$	\$
(c) Finance costs		
Bank loans and overdrafts	3,244	2,577
Other loans	3,278	25,257
Unwinding of discount on secured liabilities	90,745	27,772
Total finance costs	<u>97,267</u>	<u>55,606</u>

AVITA MEDICAL LIMITED
 NOTES TO THE PRELIMINARY FINAL REPORT
 FOR THE YEAR ENDED 30 JUNE 2009

2. REVENUES AND EXPENSES (continued)

	Consolidated	
	2009	2008
	\$	\$
(d) Depreciation, impairment and amortisation included in income statement		
Depreciation	317,325	217,129
(Profit) / Loss on disposal of plant & equipment	(895)	1,528
Amortisation of intangible assets	609,000	232,000
Impairment of goodwill	-	7,925,297

	Consolidated	
	2009	2008
	\$	\$
(e) Lease payments and other expenses included in income statement		
Minimum lease payments – operating lease	223,151	254,473

	Consolidated	
	2009	2008
	\$	\$
(f) Employee benefits expense		
Wages and salaries	2,602,624	2,024,059
Defined contribution superannuation expense	184,380	185,248
Termination benefits	153,561	43,343
Share-based payments expense	127,321	91,064
	<u>3,067,886</u>	<u>2,252,650</u>

3. LOSS PER SHARE

Basic loss per share amounts are calculated by dividing the net loss for the year attributable to ordinary equity holders of the parent by the weighted average number of ordinary shares outstanding during the year.

Diluted earnings per share amounts are calculated by dividing the net loss for the year attributable to ordinary equity holders of the parent by the weighted average number of ordinary shares outstanding during the year plus the weighted average number of ordinary shares that would be issued on the conversion of all the dilutive potential ordinary shares into ordinary shares.

The following reflects the income and share data used in the basic and diluted loss per share computations:

	Consolidated	
	2009	2008
	\$	\$
Net loss attributable to ordinary equity holders of the parent	(5,128,292)	(12,188,280)
Weighted average number of ordinary shares for basic loss per share	<u>93,473,913</u>	<u>59,864,420</u>

There have been no other transactions involving ordinary shares or potential ordinary shares between the reporting date and the date of completion of these financial statements.

AVITA MEDICAL LIMITED
 NOTES TO THE PRELIMINARY FINAL REPORT
 FOR THE YEAR ENDED 30 JUNE 2009

4. CURRENT ASSETS - CASH AND CASH EQUIVALENTS

	Consolidated	
	2009	2008
	\$	\$
Cash at bank and in hand	747,034	1,593,943
Short-term deposits	2,730,070	6,870,726
	<u>3,477,104</u>	<u>8,464,669</u>

5. CURRENT ASSETS - OTHER FINANCIAL ASSETS

	Consolidated	
	2009	2008
	\$	\$
Secured bank deposits (note 8)	400,000	400,000

An amount of \$600,000 held on deposit is secured against the vendor liability included in notes 11 and 14.

6. CURRENT ASSETS - TRADE AND OTHER RECEIVABLES

	Consolidated	
	2009	2008
	\$	\$
Trade receivables	590,209	629,799
Allowance for impairment loss	(78,541)	(20,000)
Other receivables	145,604	520,726
Carrying amount of trade and other receivables	<u>657,272</u>	<u>1,130,525</u>

7. CURRENT ASSETS - INVENTORIES

	Consolidated	
	2009	2008
	\$	\$
Raw materials and components (at cost)	705,026	450,336
Finished goods (at cost)	178,301	297,183
Total inventories at the lower of cost and net realisable value	<u>883,327</u>	<u>747,519</u>

AVITA MEDICAL LIMITED
 NOTES TO THE PRELIMINARY FINAL REPORT
 FOR THE YEAR ENDED 30 JUNE 2009

8. NON-CURRENT ASSETS – OTHER FINANCIAL ASSETS

	Consolidated	
	2009	2008
	\$	\$
Secured bank deposits	200,000	400,000

9. NON-CURRENT ASSETS - PLANT & EQUIPMENT

(a) Reconciliation of carrying amounts at the beginning and end of the period

	Consolidated	
	<i>Plant and Equipment</i>	<i>Total</i>
	\$	\$
Year ended 30 June 2009		
At 1 July 2008, net of accumulated depreciation	388,164	388,164
Additions	88,277	88,277
Disposals	(4,559)	(4,559)
Depreciation charge for the year	(317,325)	(317,325)
At 30 June 2009, net of accumulated depreciation	154,557	154,557
At 30 June 2009		
Cost	1,597,601	1,597,601
Accumulated depreciation	(1,443,044)	(1,443,044)
Net carrying amount	154,557	154,557

	Consolidated	
	<i>Plant and Equipment</i>	<i>Total</i>
	\$	\$
Year ended 30 June 2008		
At 1 July 2007, net of accumulated depreciation	319,544	319,544
Acquisition of subsidiary	189,989	189,989
Additions	112,411	112,411
Disposals	(16,651)	(16,651)
Depreciation charge for the year	(217,129)	(217,129)
At 30 June 2008, net of accumulated depreciation	388,164	388,146
At 30 June 2008		
Cost	1,555,677	1,555,677
Accumulated depreciation	(1,167,513)	(1,167,513)
Net carrying amount	388,164	388,146

AVITA MEDICAL LIMITED
 NOTES TO THE PRELIMINARY FINAL REPORT
 FOR THE YEAR ENDED 30 JUNE 2009

10. NON-CURRENT ASSETS - INTANGIBLE ASSETS AND GOODWILL

(a) Reconciliation of carrying amount at the beginning and end of the period

	Consolidated			
	Patents and Trademarks \$	Brands \$	Goodwill \$	Total \$
Year ended 30 June 2009				
At 1 July 2008 net of accumulated amortisation and impairment	4,158,888	253,000	-	4,411,888
Amortisation	(564,000)	(45,000)	-	(609,000)
At 30 June 2009 net of accumulated amortisation and impairment	<u>3,594,888</u>	<u>208,000</u>	<u>-</u>	<u>3,802,888</u>
At 30 June 2009				
Cost (gross carrying amount)	14,426,268	270,000	7,925,297	22,621,565
Accumulated amortisation and impairment	(10,831,380)	(62,000)	(7,925,297)	(18,818,677)
Net carrying amount	<u>3,594,888</u>	<u>208,000</u>	<u>-</u>	<u>3,802,888</u>

	Consolidated			
	Patents and Trademarks \$	Brands \$	Goodwill \$	Total \$
Year ended 30 June 2008				
At 1 July 2007 net of accumulated amortisation and impairment	-	-	-	-
Acquisition of subsidiary	4,373,888	270,000	7,925,297	12,569,185
Impairment	-	-	(7,925,297)	(7,925,297)
Amortisation	(215,000)	(17,000)	-	(232,000)
At 30 June 2008 net of accumulated amortisation and impairment	<u>4,158,888</u>	<u>253,000</u>	<u>-</u>	<u>4,411,888</u>
At 30 June 2008				
Cost (gross carrying amount)	14,426,268	270,000	7,925,297	22,621,565
Accumulated amortisation and impairment	(10,267,380)	(17,000)	(7,925,297)	(18,209,677)
Net carrying amount	<u>4,158,888</u>	<u>253,000</u>	<u>-</u>	<u>4,411,888</u>

FOR THE YEAR ENDED 30 JUNE 2009

11. CURRENT LIABILITIES - TRADE AND OTHER PAYABLES

	Consolidated	
	2009 \$	2008 \$
Trade payables	315,770	736,370
Accruals and other payables	370,754	1,023,118
Secured liabilities – vendor	408,513	380,335
Carrying amount of trade and other payables	<u>1,095,037</u>	<u>2,139,823</u>

12. CURRENT LIABILITIES - INTEREST BEARING LOANS AND BORROWINGS

	Consolidated	
	2009 \$	2008 \$
Bank term loan	-	33,334
Total	<u>-</u>	<u>33,334</u>

13. CURRENT LIABILITIES - PROVISIONS

	Consolidated	
	Employee benefits \$	Total \$
Current		
At 1 July 2008	52,721	52,721
Provided	23,833	23,833
At 30 June 2009	<u>76,554</u>	<u>76,554</u>

14. NON-CURRENT LIABILITIES

	Consolidated	
	2009 \$	2008 \$
Bank term loan	-	19,297
Secured liabilities – vendor	67,992	417,083
Total	<u>67,992</u>	<u>436,380</u>

AVITA MEDICAL LIMITED
 NOTES TO THE PRELIMINARY FINAL REPORT
 FOR THE YEAR ENDED 30 JUNE 2009

15. CONTRIBUTED EQUITY

	Consolidated	
	2009	2008
	\$	\$
<i>Ordinary shares</i>		
Issued and fully paid	86,824,320	86,824,320

	Number	\$
<i>Movement in ordinary shares on issue</i>		
At 1 July 2008	93,473,913	86,824,320
Issue of shares	-	-
Conversion of options	-	-
At 30 June 2009	93,473,913	86,824,320

16. ACCUMULATED LOSSES AND RESERVES

(a) Movements in accumulated losses were as follows:

	Consolidated	
	2009	2008
	\$	\$
Balance 1 July	(76,271,930)	(64,083,650)
Net loss	(5,128,292)	(12,188,280)
Balance 30 June	(81,400,222)	(76,271,930)

(b) Other Reserves

	Consolidated			Total
	Option premium reserve	Employee equity benefits reserve	Foreign exchange translation reserve	
	\$	\$	\$	\$
At 1 July 2007	2,186,695	785,048	(42,646)	2,929,097
Currency translation differences issue of options	-	-	(28,696)	(28,696)
At 30 June 2008	2,277,759	785,048	(71,342)	2,991,465
Currency translation differences	-	-	46,997	46,997
Cost of share based payment	-	127,321	-	127,321
At 30 June 2009	2,277,759	912,369	(24,345)	3,165,783

AVITA MEDICAL LIMITED
NOTES TO THE PRELIMINARY FINAL REPORT
FOR THE YEAR ENDED 30 JUNE 2009

17. SIGNIFICANT INFORMATION AND COMMENTARY

The loss attributable to members of Avita Medical Limited for the year ended 30 June 2009 was \$5,128,292 which compares to a loss of \$12,188,280 for the year ended 30 June 2008. The decrease in loss is due to the impairment of goodwill of \$7,925,297 in the prior year. Sale of goods was up 67% from the prior year reflecting the impact of the Visiomed acquisition in February 2008.

Operating costs for the year excluding amortisation and impairment of intangible assets were \$6,817,144 (2008: \$5,836,756) representing an increase of 17%.

The consolidated cash position at 30 June 2009 is \$3,477,104 (2008: \$8,464,669).

For personal use

AVITA MEDICAL LIMITED
 NOTES TO THE PRELIMINARY FINAL REPORT
 FOR THE YEAR ENDED 30 JUNE 2009

18. SEGMENT INFORMATION

The Group's primary segment reporting format is geographic segments. Following the merger with Visiomed Group Ltd the Group is now active in the regenerative medicine and respiratory markets.

The following tables present revenue and profit information and certain asset and liability information regarding geographic segments for the years ended 30 June 2009 and 30 June 2008.

	<i>Continuing Operations</i>			
	<i>Asia Pacific</i>	<i>Europe</i>	<i>Americas</i>	<i>Total</i>
	\$	\$	\$	\$
Year ended 30 June 2009				
Revenue				
Sales to external customers	1,997,467	329,891	52,788	2,380,147
Other revenues from external customers	598,652	1	-	598,653
Total segment Revenue	2,596,119	329,892	52,788	2,978,800
Non-segment revenues				5,654
Finance revenue				334,686
Other income				-
Total consolidated revenue				3,319,140
Result				
Segment results	1,029,687	(1,844,304)	(1,576,933)	(2,391,550)
Non-segment result				(2,127,742)
Amortisation of intellectual property				(609,000)
Impairment of intangible assets				-
Loss before income tax				(5,128,292)
Income tax benefit/(expense)				-
Net loss for the year				(5,128,292)
Assets and liabilities				
<i>Continuing Operations</i>				
	<i>Asia Pacific</i>	<i>Europe</i>	<i>Americas</i>	<i>Total</i>
	\$	\$	\$	\$
Year ended 30 June 2009				
Assets and liabilities				
Segment assets	1,515,334	691,089	690,019	2,896,442
Unallocated assets				6,933,022
Total Assets				9,829,464
Segment liabilities	597,673	259,979	55,964	913,616
Unallocated liabilities				325,967
Total liabilities				1,239,583
Other segment information				
Capital expenditure	4,767	74,208	9,302	88,277
Depreciation	132,212	181,143	3,970	317,325
Amortisation and impairment	-	-	-	609,000

AVITA MEDICAL LIMITED
 NOTES TO THE PRELIMINARY FINAL REPORT
 FOR THE YEAR ENDED 30 JUNE 2009

18. SEGMENT INFORMATION (continued)

	<i>Continuing Operations</i>			<i>Total</i>
	<i>Asia Pacific</i>	<i>Europe</i>	<i>Americas</i>	
	\$	\$	\$	\$
Year ended 30 June 2008				
Revenue				
Sales to external customers	839,478	214,617	30,992	1,085,087
Other revenues from external customers	171,501	-	-	171,501
Total segment Revenue	<u>1,010,979</u>	<u>214,617</u>	<u>30,992</u>	<u>1,256,588</u>
Non-segment revenues				
Finance revenue				698,418
Other income				<u>7,637</u>
Total consolidated revenue				<u>1,962,643</u>
Result				
Segment results	(1,020,315)	(2,463,018)	(882,696)	(4,366,029)
Non-segment result				(22,656)
Amortisation of intellectual property				(232,000)
Impairment of intangible assets				<u>(7,925,297)</u>
Loss before income tax				(12,545,982)
Income tax benefit/(expense)				<u>357,702</u>
Net loss for the year				<u>(12,188,280)</u>

	<i>Continuing Operations</i>			<i>Total</i>
	<i>Asia Pacific</i>	<i>Europe</i>	<i>Americas</i>	
	\$	\$	\$	\$
Year ended 30 June 2008				
Assets and liabilities				
Segment assets	1,951,926	948,676	262,546	3,163,148
Unallocated assets				13,042,965
Total Assets				<u>16,206,113</u>
Segment liabilities	738,829	735,168	97,606	1,571,603
Unallocated liabilities				1,090,655
Total liabilities				<u>2,662,258</u>
Other segment information				
Capital expenditure	<u>11,943</u>	<u>100,468</u>	<u>-</u>	<u>112,411</u>
Depreciation	34,360	158,940	23,829	217,129
Amortisation and impairment	<u>8,157,297</u>	<u>-</u>	<u>-</u>	<u>8,157,297</u>

For personal use only

Annual meeting

The annual meeting will be held as follows:

Place	To be confirmed
Date	Provisionally set as 10 November 2009
Time	2pm (WST)
Approximate date the +annual report will be available	21 October 2009

Compliance statement

- 1 This report has been prepared in accordance with AASB Standards, other AASB authoritative pronouncements and Urgent Issues Group Consensus Views or other standards acceptable to ASX (see note 12).

Identify other standards used

- 2 This report, and the +accounts upon which the report is based (if separate), use the same accounting policies.

- 3 This report does give a true and fair view of the matters disclosed

- 4 This report is based on +accounts to which one of the following applies.

(Tick one)

- | | | | |
|-------------------------------------|---|--------------------------|---|
| <input type="checkbox"/> | The +accounts have been audited. | <input type="checkbox"/> | The +accounts have been subject to review. |
| <input checked="" type="checkbox"/> | The +accounts are in the process of being audited or subject to review. | <input type="checkbox"/> | The +accounts have <i>not</i> yet been audited or reviewed. |

- 5 The entity has a formally constituted audit committee.

Sign here:

Date: 31 August 2009

Print name: William Dolphin
Chief Executive Officer

For personal use only